RT Journal Article
SR Electronic
T1 Systematic surveillance of SARS-CoV-2 reveals dynamics of variant mutagenesis and transmission in a large urban population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.25.24311007
DO 10.1101/2024.07.25.24311007
A1 Aynaud, Marie-Ming
A1 Caldwell, Lauren
A1 Al-Zahrani, Khalid N.
A1 Barutcu, Seda
A1 Chan, Kin
A1 Obersterescu, Andreea
A1 Ogunjimi, Abiodun A.
A1 Jin, Min
A1 Zakoor, Kathleen-Rose
A1 Patel, Shyam
A1 Padilla, Ron
A1 Jen, Mark
A1 Veniegas, Princess Mae
A1 Dewsi, Nursrin
A1 Yonathan, Filiam
A1 Zhang, Lucy
A1 Ayson-Fortunato, Amelia
A1 Aquino, Analiza
A1 Krzyzanowski, Paul
A1 Simpson, Jared
A1 Bartlett, John
A1 Lungu, Ilinca
A1 Wouters, Bradly G.
A1 Rini, James M.
A1 Gekas, Michael
A1 Poutanen, Susan
A1 Pelletier, Laurence
A1 Mazzulli, Tony
A1 Wrana, Jeffrey L.
YR 2024
UL http://medrxiv.org/content/early/2024/07/29/2024.07.25.24311007.abstract
AB Highly mutable pathogens generate viral diversity that impacts virulence, transmissibility, treatment, and thwarts acquired immunity. We previously described C19-SPAR-Seq, a high-throughput, next-generation sequencing platform to detect SARS-CoV-2 that we deployed to systematically profile variant dynamics of SARS-CoV-2 for over 3 years in a large, North American urban environment (Toronto, Canada). Sequencing of the ACE2 receptor binding motif and polybasic furin cleavage site of Spike in over 70,000 patients revealed that population sweeps of canonical variants of concern (VOCs) occurred in repeating wavelets. Furthermore, we found that subvariants and putative quasi-species with alterations characteristic of future VOCs and/or predicted to be functionally important arose frequently, but always extinguished. Systematic screening of functionally relevant domains in pathogens could thus provide a powerful tool for monitoring spread and mutational trajectories, particularly those with zoonotic potential.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Canadian Institutes of Health Research (Grant #177705)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mount Sinai Hospital Research Ethics Board in Toronto, Canada gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes